olmesartan has been researched along with tacrolimus in 4 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (tacrolimus) | Trials (tacrolimus) | Recent Studies (post-2010) (tacrolimus) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 17,757 | 2,319 | 6,661 |
| Protein | Taxonomy | olmesartan (IC50) | tacrolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 7.18 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.58 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 0.385 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0021 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | 0.2547 | |
| Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform | Homo sapiens (human) | 0.0148 | |
| Splicing factor 3B subunit 3 | Homo sapiens (human) | 0.0123 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 3.3 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 3.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Al-Harbi, MM; Al-Harbi, NO; Alabidy, AD; Almukhallafi, AF; Imam, F; Iqbal, M; Nadeem, A; Sayed-Ahmed, MM | 1 |
| Al-Harbi, MM; Al-Harbi, NO; Al-Hosaini, KA; Bahashwan, S; Imam, F; Iqbal, M; Nadeem, A; Rahman, S | 1 |
4 other study(ies) available for olmesartan and tacrolimus
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Olmesartan attenuates tacrolimus-induced biochemical and ultrastructural changes in rat kidney tissue.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcineurin Inhibitors; Imidazoles; Kidney Diseases; Kidney Tubules, Proximal; Male; Mitochondria; Podocytes; Rats; Rats, Wistar; Tacrolimus; Tetrazoles | 2014 |
Protection against tacrolimus-induced cardiotoxicity in rats by olmesartan and aliskiren.
Topics: Amides; Animals; Fumarates; Heart; Imidazoles; Immunosuppressive Agents; Male; Myocardium; Rats; Rats, Wistar; Tacrolimus; Tetrazoles | 2014 |